Finally, we map IMF groups to actionability, PD-1 blockade for MSI-H/dMMR disease, encorafenib–cetuximab for BRAF V600E tumors, and microenvironment-modulating opportunities (e.g., TGF-β targeting) for F-high phenotypes, illustrated by a conceptual diagram (Figure 1) and resources for trial design and tumor boards [10,11,13,15,16]. This evidence concerns the gene TGFB1 and neoplasm.